# Commission Implementing Regulation (EU) 2015/1013 of 25 June 2015 laying down rules in respect of Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors (Text with EEA relevance), Division 14: Box 19:

Extent: E+W+S+N.I.

Indicate in block letters the name of the applicant or, where appropriate, of the authorised representative who signs this application.
The signature by the applicant or authorised representative ... indicates that the person concerned is declaring that all the particulars provided on the application are correctly and fully stated. Without prejudice to the possible application of penal provisions, this declaration is equivalent to the engagement of responsibility, under the provisions in force ..., in respect of the following:
the accuracy of the information given in the declaration;
the authenticity of any documents attached;
the observance of all the obligations inherent in the export of scheduled substances listed in the Annex to Regulation (EC) No 111/2005.
Whenever the authorisation is issued by means of a computerised procedure, that authorisation may not contain the signature of the applicant in this box, if the application as such contains such signature.

---
Source: https://www.legislation.gov.uk/eur/2015/1013/annex/III/annotations/1/annotation/14 (the official version)
Page: https://openlegislation.uk/eu-regulation-2015-1013/annex-III/annotations/1/annotation/14
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.